Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer


Por: Ganz P, Bandos H, Spanic T, Friedman S, Mueller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E, Armstrong A, Im S, Song C, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee K, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek S, Bane C, Mccarron E, Mita M, Rossi G, Rastogi P, Fielding A, Gelber R, Scheepers E, Cameron D, Garber J, Geyer C, Tutt A

Publicada: 10 abr 2024
Resumen:

ISSN: 0732183X





Journal Of Clinical Oncology
Editorial
AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 42 Número: 11
Páginas:
WOS Id: 001236945700012
ID de PubMed: 38301187

MÉTRICAS